These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Chemotherapy of head and neck cancer]. Author: Kohno N, Nakazawa E, Kusunoki M, Nishiya M. Journal: Gan To Kagaku Ryoho; 1996 Feb; 23(3):277-82. PubMed ID: 8712819. Abstract: Squamous cell carcinoma of the head and neck is a chemotherapeutically responsive tumor. Methotrexate, cisplatin, 5-fluorouracil and bleomycin in various combinations have achieved tumor regression, with complete or partial response, in 60-90% of previously untreated patients. The response to chemotherapy, however, is often short-lived, and conventional treatment has produced little impact on survival. To date, neo-adjuvant and/or adjuvant chemotherapy have also failed to demonstrate any impact on the survival rate, although subset analysis has indicated a possible survival benefit. Furthermore, larynx preservation and reduction in incidence of metastasis have been demonstrated. Concomitant chemoradiotherapy has some positive results in disease free survival and/or overall survival. In this report, we reviewed the literature on neoadjuvant chemotherapy, adjuvant chemotherapy, salvage chemotherapy and concomitant chemoradiotherapy for advanced head and neck cancer, and analyzed their efficacy.[Abstract] [Full Text] [Related] [New Search]